Glaukos Corp. is listed today as Glaukos Corporation: market value, financials and filings are on its company page.
Funding rounds
5 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2013 | $30 M | No. 5 | $10 to $50 million | equity | SEC | |
| Oct 2012 | $6 M | No. 4 | $2 to $10 million | debt, options | SEC | |
| Aug 2012 | $5 M | No. 3 | $2 to $10 million | debt, options | SEC | |
| Jan 2011 | $30 M | No. 2 | $10 to $50 million | equity | SEC | |
| Sep 2010 | $6 M | No. 1 | $2 to $10 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Glaukos Corporation, its revenue in fiscal 2025 came from these product and service lines: Glaucoma $421.07 million (83%), Corneal Health $86.37 million (17%).
Annual report (SEC XBRL) · Dec 2025
Glaukos Corp. chose not to state its revenue in its newest notice of a funding round (Jan 2013).
SEC Form D · Jan 2013
The industry group it chose in its notices: Other Health Care.
SEC Form D · Jan 2013
Products and services#
No products or services of Glaukos Corp. are on record.
Investors#
24 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Chris M. Calcaterra | Person | not stated | not stated | Held Series D preferred stock (Form 3, 2015) | SEC Form 3 |
| Domain Partners IV LP | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Domain Partners VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| DP IV Associates LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| DP VIII Associates, L.P. | Fund or asset manager | not stated | not stated | Held Series E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| FHM V, LLC | Other | not stated | not stated | Held Series C, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| FHM V, LP | Fund or asset manager | not stated | not stated | Held Series C, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Frazier Healthcare V, LP | Fund or asset manager | not stated | not stated | Held Series C, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| InterWest Management Partners IX, LLC | Fund or asset manager | not stated | not stated | Held Series C, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| InterWest Partners IX, LP | Fund or asset manager | not stated | not stated | Held Series C, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Meritech Capital Affiliates III L.P. | Fund or asset manager | not stated | not stated | Held Series E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Meritech Capital Associates III L.L.C. | Fund or asset manager | not stated | not stated | Held Series E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Meritech Capital Partners III LP | Fund or asset manager | not stated | not stated | Held Series E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Montreux Equity Management IV, LLC | Fund or asset manager | not stated | not stated | Held Series C, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Montreux Equity Partners IV LP | Private equity | not stated | not stated | Held Series C, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Montreux IV Associates, LLC | Other | not stated | not stated | Held Series C, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series D, E and F preferred stock, 10% owner, director (Form 3, 2015) | SEC Form 3 |
| OrbiMed Capital GP III LLC | Fund or asset manager | not stated | not stated | Held Series D, E and F preferred stock, 10% owner, director (Form 3, 2015) | SEC Form 3 |
| Richard L. Harrison | Person | not stated | not stated | Held Series D preferred stock (Form 3, 2015) | SEC Form 3 |
| Versant Affiliates Fund I-A LP | Fund or asset manager | not stated | not stated | Held Series A, B, C, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Versant Affiliates Fund I-B LP | Fund or asset manager | not stated | not stated | Held Series A, B, C, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Versant Side Fund I LP | Fund or asset manager | not stated | not stated | Held Series A, B, C, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Versant Venture Capital I LP | Venture capital | not stated | not stated | Held Series A, B, C, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Versant Ventures I LLC | Venture capital | not stated | not stated | Held Series A, B, C, D, E and F preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 20 investors.
Largest shareholders today
Institutions holding Glaukos Corporation shares, as of Sep 30, 2026.
- BlackRock, Inc.$1.5 B15.75%
- Janus Henderson Group Ltd.$760 M7.82%
- Vanguard Portfolio Management LLC$542 M5.58%
- Primecap Management Co/ca/$505 M5.20%
- FMR LLC$471 M4.84%
- Vanguard Capital Management LLC$418 M4.30%
- State Street Corp$380 M3.91%
- Millennium Management LLC$240 M2.47%
- Geode Capital Management, LLC$238 M2.45%
- Invesco Ltd.$203 M2.09%
- Goldman Sachs Group Inc$168 M1.73%
- Capital World Investors$167 M1.72%
- Alliancebernstein L.P.$160 M1.65%
- Holocene Advisors, LP$139 M1.43%
- Charles Schwab Investment Management Inc$133 M1.36%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Olav B. Bergheim | Executive officer | Jan 2013 |
| Richard W. Harrison | Executive officer | Jan 2013 |
| Thomas W. Burns | Executive officer | Jan 2013 |
| Richard L. Harrison | Executive officer | Feb 2011 |
| Daniel K. Turner | Director | Jan 2013 |
| Gilbert H. Kliman | Director | Jan 2013 |
| Jonathan T. Silverstein | Director | Jan 2013 |
| Olav B. Bergheim | Director | Jan 2013 |
| Paul S. Madera | Director | Jan 2013 |
| Robert J. More | Director | Jan 2013 |
| Thomas W. Burns | Director | Jan 2013 |
| William J. Link | Director | Jan 2013 |
| Manish N. Chapekar | Director | Feb 2011 |
Went public since 2015. Its SEC number is that of a company listed on a stock exchange.